Rentschler Biotechnologie GmbH is expanding its facilities, buildings and laboratory units at the company’s site in Laupheim, Germany. This will increase production capacities for antibodies and mammalian cell culture-derived proteins. “By expanding our production capacity we will establish Rentschler Biotechnologie as a market supplier of antibodies,” said Dr. Nikolaus F. Rentschler, the company’s chief executive officer. The Rentschler Group will invest $64 million in its biot...